Cofoe Medical Technology (301087) Q2 2024 earnings summary

Executive summary

• H1 2024 revenue rose 2.60% YoY to ¥1.559bn, while net income attributable to shareholders fell 7.00% to ¥185.0m.

• Q2 accelerated: revenue increased 13.21% YoY to ¥751m, attributable net income rose 30.06% to ¥84m, and adjusted net income rose 62.14% to ¥74m.

• Core-category growth, higher gross margin and online sales gains supported performance; elevated selling costs and declines in several product categories weighed on H1 results.

Financial highlights

• H1 revenue was ¥1.559bn, up 2.60% YoY; operating costs fell 6.19% to ¥768.8m.

• Net income attributable to shareholders was ¥185.0m, down 7.00%; adjusted net income excluding non-recurring items was ¥166.0m, down 2.76%.

• Q2 revenue grew 13.21% YoY; Q2 attributable net income increased 30.06% and adjusted net income increased 62.14%.

• Operating cash flow was ¥307.0m, down 11.21% YoY; investment cash flow was ¥21.2m versus an outflow of ¥236.8m a year earlier.

• Selling expenses rose 31.99% to ¥466.7m, driven by store expansion, marketing and promotion; R&D spending declined 17.32% to ¥45.8m.

Outlook and guidance

• Strategic priorities include focusing on core categories, accelerating product iteration, improving manufacturing efficiency and expanding interest-based e-commerce.

• More than 40 new products launched in H1; ongoing work includes product development, digital operations, cost reduction and channel optimization.

• Industry growth prospects are supported by aging demographics, home-based care demand, policy support and faster online medical-device sales; no quantitative financial outlook is cited here.